Dr. Christina Mack has been named chief scientific officer for IQVIA's Real World Solutions (RWS) division, effective July 7, 2022. Christina will take over for Dr. Nancy Dreyer, who will retire after nearly two decades with IQVIA.

In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina’s career at IQVIA has included several leadership roles, all focused on the use of real-world evidence to improve patient care and patient outcomes. Prior to this appointment, Christina served as vice president of Epidemiology and Clinical Evidence, where she led the development of real-world evidence platforms for infectious diseases, medical devices, and sports injury studies. Christina also developed scientific research protocols under an agile analytics model conceived for the avian influenza pandemic, which were used to accelerate the understanding of COVID-19 diagnosis, transmission, and clinical course.

Dr. Mack’s multi-disciplinary skills span technology and science. Christina holds an undergraduate degree in Computer Science Engineering from the University of Notre Dame, as well as a Master of Science in Public Health and a PhD in Epidemiology from the University of North Carolina at Chapel Hill. Dr. Mack co-chairs numerous industry committees and is an adjunct associate professor at the UNC-Chapel Hill School of Public Health. Dr. Mack also serves on the advisory board of the Carolina Health Informatics Program, the ISPE Real World Evidence task force, and co-chairs the Medical Device Epidemiology Network Scientific Oversight Committee.

“Christina is widely respected within IQVIA and across the industry as an experienced epidemiologist and leader. This will be a seamless transition,” said Rob Kotchie, president of Real World Solutions. “I would like to thank Nancy for her strong leadership and pivotal contributions to RWS. She leaves behind a strong legacy and foundation upon which Christina will continue to build. Dr. Dreyer’s thought leadership and guidance have been an asset to our team and to the larger IQVIA organization.”

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 79,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Source: IQVIA newsroom